stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Net margin
Haemonetics Corporation's net margin over the twelve months to 30 September 2026 was 7.52%, up 0.2 percentage points from fiscal 2026 (7.29%). Over the past ten years it has ranged from −6.12% (fiscal 2016) to 12.3% (fiscal 2025); the current reading is higher than 58% of that period. That is above the Medical Devices industry median of −14.5% and above the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2026 | 7.29% | (5.03) |
| FY2025 | 12.3% | 3.34 |
| FY2024 | 8.98% | (0.89) |
| FY2023 | 9.87% | 5.50 |
| FY2022 | 4.37% | (4.76) |
| FY2021 | 9.13% | 1.39 |
| FY2020 | 7.74% | 2.05 |
| FY2019 | 5.69% | 0.65 |
| FY2018 | 5.04% | 8.00 |
| FY2017 | −2.96% | 3.16 |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2026 | 12.9% | 3.21 |
| Jun 2026 | 9.73% | 15.55 |
| Mar 2026 | −5.82% | (19.02) |
| Dec 2025 | 13.2% | 1.38 |
| 43 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | 39.5% |
| BIO Bio-Rad Laboratories, Inc. compare | 39.5% |
| LIVN LivaNova PLC compare | 13.0% |
| HAE Haemonetics Corporation | 7.52% |
| ITGR Integer Holdings Corporation compare | 5.68% |
| IRTC iRhythm Holdings, Inc. compare | −4.52% |
| BRKR Bruker Corporation compare | −4.76% |
| AXGN AxoGen, Inc. compare | −12.0% |
| TXG 10x Genomics compare | −12.2% |
| Medical Devices industry median | −14.5% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on HAE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement